February 2022
"InterAx Biotech AG and Boehringer Ingelheim take first steps towards collaborating to unlock orphan targets leveraging InterAx AI driven discovery platform.
Collaborative efforts aim to accelerate and improve the prediction of first-in-class small molecule agonists for a challenging orphan GPCR for a highly relevant therapeutic need. 💊
InterAx Biotech AG discovery platform was already successfully applied in projects with biopharmaceutical companies and also used in-house to discover first-in-class compounds for a novel oncology target that are now being tested in-vivo.
#ai #biotech #systemsbiology #drugdiscovery #gpcr #deeptech #orphandrugs #pharma #partnerships #AI4drugdiscovery"
Comments